ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs MXN
16.7282
0.38%
Brent Oil
81.25
-0.34%
Bitcoin
67,859.18
-1.80%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
23/05/202416:00Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
23/05/202416:00Business WireMerck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
23/05/202416:00GlobeNewswire Inc.IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingNASDAQ:INABIN8bio Inc
23/05/202416:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
23/05/202416:00Business WireSOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
23/05/202416:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
23/05/202416:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingTG:2GHMerus NV
23/05/202416:00GlobeNewswire Inc.Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:BPTHBio Path Holdings Inc
23/05/202416:00GlobeNewswire Inc.Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
23/05/202416:00Business WireObsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23/05/202416:00GlobeNewswire Inc.Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual MeetingNASDAQ:MURAMural Oncology PLC
23/05/202416:00Business WireDentalcorp Announces Annual General Meeting Voting ResultsTSX:DNTLdentalcorp Holdings Ltd
23/05/202416:00GlobeNewswire Inc.MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENTNASDAQ:MAQCMaquia Capital Acquisition Corporation
23/05/202416:00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
23/05/202416:00Business WireKlaviyo to Present at the William Blair Growth Stock ConferenceNYSE:KVYOKlaviyo Inc
23/05/202416:00Business WireOrca Bio to Present Positive Clinical Outcomes with Orca-T in Patients with AML at 2024 ASCO Annual Meeting
23/05/202416:00GlobeNewswire Inc.Timbercreek Financial Declares May 2024 DividendTSX:TFTimbercreek Financial Corp
23/05/202416:00Business WireNeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23/05/202416:00GlobeNewswire Inc.Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsTSX:THTheratechnologies Inc
23/05/202416:00GlobeNewswire Inc.Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
23/05/202416:00Business WireMenarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
23/05/202416:00GlobeNewswire Inc.Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual MeetingTG:2GHMerus NV
23/05/202416:00Business WireIambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
23/05/202416:00Business WireXspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
23/05/202416:00Business WireEMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
23/05/202416:00GlobeNewswire Inc.Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:REPLReplimune Group Inc
23/05/202416:00GlobeNewswire Inc.NVIDIA Announces Upcoming Event for Financial CommunityNASDAQ:NVDANVIDIA Corporation
23/05/202416:00Business WireCity of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23/05/202416:00Business WireAffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer
23/05/202416:00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc

Su Consulta Reciente

EU
CUNAA
Centre Hospitalier Unive...
BIT
P20LS0
NLBNPIT20LS0 20240621 33...
BOV
D1EL34M
Dell Technologies
EU
UNPA
Union Pacific
BOV
CPRL34
Canadian Pacific Kansas ...
EU
BPFBY
BPIFRF null
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados